Latest News and Press Releases

LOUISVILLE, CO--(Marketwire - September 24, 2008) - GlobeImmune, Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate,...

LOUISVILLE, CO--(Marketwire - July 9, 2008) - GlobeImmune, Inc. announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) at the...

LOUISVILLE, CO--(Marketwire - June 24, 2008) - FierceBiotech and GlobeImmune, Inc. announced today that GlobeImmune has been named to the annual FierceBiotech "Fierce 15" list, designating it as one...

LOUISVILLE, CO--(Marketwire - May 20, 2008) - GlobeImmune, Inc. announced today completion of the planned enrollment of 120 subjects in a Phase 2 clinical trial to evaluate the GI-5005 Tarmogen®...

LOUISVILLE, CO--(Marketwire - March 25, 2008) - GlobeImmune, Inc. announced today the addition of J. William Freytag, Ph.D. to its Board of Directors. "Dr. Freytag brings over 25 years of research,...

LOUISVILLE, CO--(Marketwire - March 19, 2008) - GlobeImmune, Inc. announced today the initiation of a Phase 2a clinical trial at Memorial Sloan Kettering Cancer Center (MSKCC) to evaluate...

LOUISVILLE, CO--(Marketwire - January 3, 2008) - GlobeImmune, Inc. announced today that President and Chief Executive Officer, Timothy C. Rodell, M.D., will present at the JPMorgan Healthcare...

LOUISVILLE, CO--(Marketwire - December 19, 2007) - GlobeImmune, Inc. announced today the initiation of the Company's Phase 2 clinical trial to evaluate GI-5005 Tarmogen® for the treatment of...

LOUISVILLE, CO--(Marketwire - November 6, 2007) - GlobeImmune, Inc. today announced results from the additional higher dose cohorts from the Company's randomized, placebo-controlled Phase 1b clinical...

LOUISVILLE, CO--(Marketwire - November 1, 2007) - GlobeImmune, Inc. today announced that additional high dose results from the Company's randomized, placebo-controlled Phase 1b clinical trial...